CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 22-253 & 22-254

PROPRIETARY NAME REVIEW(S)
Date: October 28, 2008

To: Russell Katz, MD, Director
Division of Neurology Products

Bob Rappaport, MD, Director
Division of Anesthesia, Analgesia and Rheumatology Products

Thru: Kristina C. Arnowine, PharmD, Acting Team Leader
Denise P. Toyer, PharmD, Deputy Director
Carol A. Holquist, RPh, Director
Division of Medication Error Prevention and Analysis

From: Loretta Holmes, BSN, PharmD, Safety Evaluator
Division of Medication Error Prevention and Analysis

Subject: Proprietary Name Review

Drug Name: Vimpal (Lacosamide) Tablets (50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg), and Injection (10 mg/mL)

Application Type/Number: NDA 22-253, NDA-22-254,

Applicant: Schwartz Biosciences, Inc.

OSE RCM #: 2008-1418

*** Note: This review contains proprietary and confidential information that should not be released to the public. ***
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXECUTIVE SUMMARY</td>
<td>3</td>
</tr>
<tr>
<td>1 BACKGROUND</td>
<td>3</td>
</tr>
<tr>
<td>1.1 Introduction</td>
<td>3</td>
</tr>
<tr>
<td>1.2 Regulatory History</td>
<td>3</td>
</tr>
<tr>
<td>1.3 Product Information</td>
<td>4</td>
</tr>
<tr>
<td>2 METHODS AND MATERIALS</td>
<td>4</td>
</tr>
<tr>
<td>2.1 Proprietary Name Risk Assessment</td>
<td>4</td>
</tr>
<tr>
<td>3 RESULTS</td>
<td>9</td>
</tr>
<tr>
<td>3.1 Proprietary Name Risk Assessment</td>
<td>9</td>
</tr>
<tr>
<td>4 DISCUSSION</td>
<td>10</td>
</tr>
<tr>
<td>4.1 Proprietary Name Risk Assessment</td>
<td>10</td>
</tr>
<tr>
<td>5 CONCLUSIONS</td>
<td>10</td>
</tr>
<tr>
<td>6 RECOMMENDATIONS</td>
<td>11</td>
</tr>
<tr>
<td>6.1 Comments to the Division</td>
<td>11</td>
</tr>
<tr>
<td>6.2 Comments to the Applicant</td>
<td>11</td>
</tr>
<tr>
<td>7 REFERENCES</td>
<td>11</td>
</tr>
<tr>
<td>APPENDICES</td>
<td>12</td>
</tr>
</tbody>
</table>
EXECUTIVE SUMMARY

The Division of Medication Error Prevention and Analysis has no objection to the use of the proprietary name, Vimpat, for this product. The results of the Proprietary Name Risk Assessment found that the proposed name, Vimpat, has some similarity to other proprietary and established drug names, but the findings of the FMEA indicate that the proposed name is not vulnerable to name confusion that could lead to medication errors.

Additionally, in OSE Review 2007-1610, we

Furthermore, during last minute label/labeling negotiations, the Applicant agreed to provide revised labels/labeling to DMEPA for review prior to marketing the 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg tablets and 10 mg/mL injection.

1 BACKGROUND

1.1 INTRODUCTION

This review was written in response to a request from the Division of Neurology Products (DNP) for re-assessment of the proposed proprietary name, Vimpat, regarding potential name confusion with other proprietary or established drug names.

1.2 REGULATORY HISTORY

The Division of Medication Error Prevention and Analysis previously reviewed the proposed tradename, Vimpat, in OSE Review 2007-1610, dated May 13, 2008 and had no objections to the use of the proposed proprietary name at that time.

Additionally,

Thus, these issues will not be addressed in this review.

The container labels and carton labeling were reviewed in OSE Review 2008-633. Our label/labeling comments from that review had not yet been sent to the Applicant as of October 23, 2008. However, the Applicant submitted revised professional sample blister card labels.

Due to the upcoming PDUFA date and the short time DMEPA was afforded to conduct this review, the Division requested comments on the revised professional sample blister card on October 23, 2008. Appendix J contains a copy of the email forwarded with DMEPA's comments. The Division forwarded DMEPA's recommendations (from OSE 2008-633 and the October 23, 2008 email) to the Applicant during the labeling negotiations.

DMEPA notes that NDA —— (lacosamide tablets for the management of neuropathic pain associated with diabetic peripheral neuropathy) received a not approvable action ——

Vimpat was recently approved (September 2008) in Europe for the treatment of partial-onset seizures.
1.3 PRODUCT INFORMATION

Vimpat (Lacosamide) is a new molecular entity indicated for the treatment of partial-onset seizures in patients with epilepsy aged 16 years and older and for management of neuropathic pain associated with diabetic peripheral neuropathy. The dosing and administration are as follows:

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Partial-onset seizures in patients with epilepsy aged 16 years and older.</strong> (The tablets and injection are indicated for partial-onset seizures)</td>
<td>The total daily dose should be divided and given two times daily. Initiate with 50 mg twice daily (100 mg/day). Can be increased at weekly intervals by 100 mg/day up to therapeutic doses of 200 mg/day to 400 mg/day. <strong>Replacement therapy</strong> for partial-onset seizures: When switching from oral to intravenous therapy, the initial total daily intravenous dosage should be equivalent to the oral total daily dosage and frequency. Vimpat can be administered without further dilution or may be mixed with a compatible diluent and infused over at least</td>
</tr>
<tr>
<td><strong>Neuropathic Pain Associated With Diabetic Peripheral Neuropathy</strong></td>
<td>b(4)</td>
</tr>
</tbody>
</table>

Vimpat will be supplied in the following dosage forms and strengths: Tablets: 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg (60-, 180- count bottles): and Injection: 10 mg/mL (20 mL single-use vial).

2 METHODS AND MATERIALS

This section describes the methods and materials used by the Division of Medication Error Prevention and Analysis conducting a proprietary name risk assessment (see 2.1 Proprietary Name Risk Assessment). The primary focus for the assessment is to identify and remedy potential sources of medication error prior to drug approval. The Division of Medication Error Prevention and Analysis defines a medication error as any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer.¹

2.1 PROPRIETARY NAME RISK ASSESSMENT

FDA’s Proprietary Name Risk Assessment considers the potential for confusion between the proposed proprietary name, Vimpat, and the proprietary and established names of drug products existing in the marketplace and those pending IND, BLA, NDA, and ANDA products currently under review by CDER.

For the proprietary name, Vimpat, the medication error staff of the Division of Medication Error Prevention and Analysis search a standard set of databases and information sources to identify names with orthographic and phonetic similarity (see Sections 2.1.1 for detail) and held a CDER Expert Panel discussion to gather professional opinions on the safety of the proposed proprietary name (see 2.1.1.2). The Division of Medication Error Prevention and Analysis normally conducts internal CDER prescription analysis studies and, when provided, external prescription analysis studies results are considered and incorporated into the overall risk assessment. However, because this name was previously evaluated, CDER prescription analysis studies were not repeated and a re-analysis of the external prescription analysis was not conducted upon this re-review of Vimpat.

The Safety Evaluator assigned to the Proprietary Name Risk Assessment is responsible for considering the collective findings, and provides an overall risk assessment of the proposed proprietary name (see detail 2.1.2). The overall risk assessment is based on the findings of a Failure Modes and Effects Analysis (FMEA) of the proprietary name, and is focused on the avoidance of medication errors. FMEA is a systematic tool for evaluating a process and identifying where and how it might fail.\textsuperscript{2} FMEA is used to analyze whether the drug names identified with look- or sound-alike similarity to the proposed name could cause confusion that subsequently leads to medication errors in the clinical setting. The Division of Medication Error Prevention and Analysis uses the clinical expertise of the medication error staff to anticipate the conditions of the clinical setting that the product is likely to be used in based on the characteristics of the proposed product.

In addition, the product characteristics provide the context for the verbal and written communication of the drug names and can interact with the orthographic and phonetic attributes of the names to increase the risk of confusion when there is overlap, or, in some instances, decrease the risk of confusion by helping to differentiate the products through dissimilarity. As such, the staff considers the product characteristics associated with the proposed drug throughout the risk assessment, since the product characteristics of the proposed may provide a context for communication of the drug name and ultimately determine the use of the product in the usual clinical practice setting.

Typical product characteristics considered when identifying drug names that could potentially be confused with the proposed drug name include, but are not limited to established name of the proposed product, the proposed indication, dosage form, route of administration, strength, unit of measure, dosage units, recommended dose, typical quantity or volume, frequency of administration, product packaging, storage conditions, patient population, and prescriber population. Because drug name confusion can occur at any point in the medication use process, the Division of Medication Error Prevention and Analysis considers the potential for confusion throughout the entire U.S. medication use process, including drug procurement, prescribing and ordering, dispensing, administration, and monitoring the impact of the medication.\textsuperscript{3}

\subsection*{2.1.1 Search Criteria}

The medication error staff consider the spelling of the name, pronunciation of the name when spoken, and appearance of the name when scripted as outlined in Appendix A. For this review, particular consideration was given to drug names beginning with the letter ‘V’ when searching to identify potentially similar drug names, as 75\% of the confused drug names reported by the USP-ISMP Medication Error Reporting Program involve pairs beginning with the same letter.\textsuperscript{4,5}


To identify drug names that may look similar to Vimpat, the Staff also consider the orthographic appearance of the name on lined and unlined orders. Specific attributes taken into consideration include the length of the name (6 letters), upstrokes (2, uppercase letter 'V' and lowercase 't'), downstrokes (one, lowercase 'p'), cross-strokes (one, lowercase 't'), and dotted letters (one, lowercase 'i'). Additionally, several letters in Vimpat may be vulnerable to ambiguity when scripted, including the letter 'V' which may appear as 'L', 'N', 'U', 'Y' or 'Z'; lowercase 'i' appear as a lowercase 'e' or 'l'; lowercase 'm' appear as a lowercase 'n' or 'v'; lowercase 'p' appear as lowercase 'j', 'p' or 'q'; lowercase 'a' appear as lowercase 'ce', 'ci' or 'e'; and lowercase 't' appear as lowercase 'l' (when the letter 't' is uncrossed) or 'x'. As such, the Staff also consider these alternate appearances when identifying drug names that may look similar to Vimpat.

When searching to identify potential names that may sound similar to Vimpat, the medication error staff search for names with similar number of syllables (two), stresses (VIM-pat or vim-PAT), and placement of vowel and consonant sounds. In addition, several letters in Vimpat may be subject to interpretation when spoken, including the letters "Vim", which may be interpreted as "Vem", "Vin", "Ven", "Bim", "Bem", "Bin", and "Ben". The Applicant’s intended pronunciation of the proprietary (VIM-pat), was also taken into consideration.

The Staff also considers the product characteristics associated with the proposed drug throughout the identification of similar drug names, since the product characteristics of the proposed drug ultimately determine the use of the product in the clinical practice setting. For this review, the medication error staff were provided with the following information about the proposed product: the proposed proprietary name (Vimpat), the established name (Lacosamide), proposed indication of use (partial-onset seizures and diabetic peripheral neuropathic pain), strengths (50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg tablets; and 10 mg/mL injection), dose (for diabetic peripheral neuropathic pain; initially 100 mg/day may gradually increase to 75 ng/day for partial onset seizures), frequency of administration (total daily dose should be divided into twice-daily dosing), route of administration (oral or intravenous) and dosage forms of the product (tablet and injection). Appendix A provides a more detailed listing of the product characteristics the medication error staff generally take into consideration.

Lastly, the medication error staff also consider the potential for the proposed name to inadvertently function as a source of error for reasons other than name confusion. Post-marketing experience has demonstrated that proprietary names (or components of the proprietary name) can be a source of error in a variety of ways. As such, these broader safety implications of the name are considered and evaluated throughout this assessment and the medication error staff provide additional comments related to the safety of the proposed name or product based on their professional experience with medication errors.

### 2.1.1.1 Databases and Information Sources

The proposed proprietary name, Vimpat, was provided to the medication error staff to conduct a search of the internet, several standard published drug product reference texts, and FDA databases to identify existing and proposed drug names that may sound-alike or look-alike to Vimpat using the criteria outlined in 2.1.1. A standard description of the databases used in the searches is provided in Section 7. To complement the process, the medication error staff use a computerized method of identifying phonetic and orthographic similarity between medication names. The program, Phonetic and Orthographic Computer Analysis (POCA), uses complex algorithms to select a list of names from a database that have some similarity (phonetic, orthographic, or both) to the trademark being evaluated. Lastly, the medication error staff review the USAN stem list to determine if any USAN stems are present within the proprietary.

---

name. The findings of the individual Safety Evaluators were then pooled and presented to the Expert Panel.

2.1.1.2 CDER Expert Panel Discussion

An Expert Panel Discussion is held by the Division of Medication Error Prevention and Analysis to gather CDER professional opinions on the safety of the product and the proprietary name, Vimpat. Potential concerns regarding drug marketing and promotion related to the proposed names are also discussed. This group is composed of the Division of Medication Error Prevention and Analysis Staff and representatives from the Division of Drug Marketing, Advertising, and Communications (DDMAC).

The pooled results of the medication error staff were presented to the Expert Panel for consideration. Based on the clinical and professional experiences of the Expert Panel members, the Panel may recommend the addition of names, additional searches by the Safety Evaluator to supplement the pooled results, or general advice to consider when reviewing the proposed proprietary name.

2.1.2 Safety Evaluator Risk Assessment of the Proposed Proprietary Name

Based on the criteria set forth in Section 2.1.1, the Safety Evaluator applies their individual expertise gained from evaluating medication errors reported to FDA to conduct a Failure Modes and Effects Analysis and provide an overall risk of name confusion. Failure Mode and Effects Analysis (FMEA) is a systematic tool for evaluating a process and identifying where and how it might fail. When applying FMEA to assess the risk of a proposed proprietary name, we seek to evaluate the potential for a proposed name to be confused with another drug name as a result of the name confusion and cause errors to occur in the medication use system. FMEA capitalizes on the predictable and preventable nature of medication errors associated with drug name confusion. FMEA allows the Agency to identify the potential for medication errors due to look- or sound-alike drug names prior to approval, where actions to overcome these issues are easier and more effective than remedies available in the post-approval phase.

In order to perform a FMEA of the proposed name, the Safety Evaluator must analyze the use of the product at all points in the medication use system. Because the proposed product is not yet marketed, the Safety Evaluator anticipates the use of the product in the usual practice settings by considering the clinical and product characteristics listed in Appendix A. The Safety Evaluator then analyzes the proposed proprietary name in the context of the usual practice setting and works to identify potential failure modes and the effects associated with the failure modes.

In the initial stage of the Risk Assessment, the Safety Evaluator compares the proposed proprietary name to all of the names gathered from the above searches, expert panel evaluation, and studies, and identifies potential failure modes by asking: "Is the name Vimpat convincingly similar to another drug name, which may cause practitioners to become confused at any point in the usual practice setting?" An affirmative answer indicates a failure mode and represents a potential for Vimpat to be confused with another proprietary or established drug name because of look- or sound-alike similarity. If the answer to the question is no, the Safety Evaluator is not convinced that the names possess similarity that would cause confusion at any point in the medication use system and the name is eliminated from further review.

In the second stage of the Risk Assessment, all potential failure modes are evaluated to determine the likely effect of the drug name confusion, by asking "Could the confusion of the drug names conceivably result in medication errors in the usual practice setting?" The answer to this question is a central component of the Safety Evaluator's overall risk assessment of the proprietary name. If the Safety Evaluator determines through FMEA that the name similarity would ultimately not be a source of

---

medication errors in the usual practice setting, the name is eliminated from further analysis. However, if
the Safety Evaluator determines through FMEA that the name similarity could ultimately cause
medication errors in the usual practice setting, the Safety Evaluator will then recommend that an alternate
proprietary name be used. In rare instances, the FMEA findings may provide other risk-reduction
strategies, such as product reformulation to avoid an overlap in strength or an alternate modifier
designation may be recommended as a means of reducing the risk of medication errors resulting from
drug name confusion.

The Division of Medication Error Prevention and Analysis will object to the use of proposed proprietary
name when one or more of the following conditions are identified in the Safety Evaluator’s Risk
Assessment:

1. DDMAC finds the proposed proprietary name misleading from a promotional perspective, and
the review Division concurs with DDMAC’S findings. The Federal Food, Drug, and Cosmetic
Act provides that labeling or advertising can misbrand a product if misleading representations are
made or suggested by statement, word, design, device, or any combination thereof, whether
through a trade name or otherwise. [21 U.S.C 321(n); see also 21 U.S.C. 352(a) & (n)].

2. The Division of Medication Error Prevention and Analysis identifies that the proposed
proprietary name is misleading because of similarity in spelling or pronunciation to another
proprietary or established name of a different drug or ingredient [CFR 201.10(c)(5)].

3. FMEA identifies potential for confusion between the proposed proprietary name and other
proprietary or established drug names, and demonstrates that medication errors are likely to result
from the drug name confusion under the conditions of usual clinical practice.

4. The proposed proprietary name contains an USAN stem, particularly in a manner that is
contradictory to the USAN Council’s definition.

5. Medication error staff identify a potential source of medication error within the proposed
proprietary name. The proprietary name may be misleading, or inadvertently introduce ambiguity
and confusion that leads to errors. Such errors may not necessarily involve confusion between
the proposed drug and another drug product.

In the event that the Division of Medication Error Prevention and Analysis objects to the use of the
proposed proprietary name, based upon the potential for confusion with another proposed (but not yet
approved) proprietary name, we will provide a contingency objection based on the date of approval:
whichever product is awarded approval first has the right to the use the name, while we will recommend
that the second product to reach approval seek an alternative name.

If none of these conditions are met, then we will not object to the use of the proprietary name. If any of
these conditions are met, then we will object to the use of the proprietary name. The threshold set for
objection to the proposed proprietary name may seem low to the Sponsor/Applicant; however, the safety
concerns set forth in criteria 1 through 5 are supported either by FDA Regulation or by external
healthcare authorities, including the Institute of Medicine, World Health Organization, Joint Commission,
and Institute for Safe Medication Practices, have examined medication errors resulting from look- or
sound-alike drug names and called for Regulatory Authorities to address the issue prior to approval.

Furthermore, the Division of Medication Error Prevention and Analysis contends that the threshold set for
the Proprietary Name Risk Assessment is reasonable because proprietary drug name confusion is a
predictable and preventable source of medication error that, in many instances, can be identified and
remedied prior to approval to avoid patient harm.

Additionally, post-marketing experience has demonstrated that medication errors resulting from drug
name confusion are notoriously difficult to remedy post-approval. Educational efforts and so on are low-
leverage strategies that have proven to have limited effectiveness at alleviating the medication errors
involving drug name confusion. Higher-leverage strategies, such as drug name changes, have been undertaken in the past; but at great financial cost to the Sponsor, and at the expense of the public welfare, not to mention the Agency’s credibility as the authority responsible for the approving the error-prone proprietary name. Moreover, even after Sponsor’s have changed a product’s proprietary name in the post-approval phase, it is difficult to eradicate the original proprietary name from practitioner’s vocabulary, and as such, the Agency has continued to receive reports of drug name confusion long after a name change in some instances. Therefore, we believe that post-approval efforts at reducing name confusion errors should be reserved for those cases in which the potential for name confusion could not be predicted prior to approval (e.g. new form introduced like Lamisil) (see limitations of the process in Section 4).

If the Division of Medication Error Prevention and Analysis objects to a proposed proprietary name on the basis that drug name confusion could lead to medication errors, the FMEA process is used to identify strategies to reduce the risk of medication errors. The Division of Medication Error Prevention and Analysis is likely to recommend that the Sponsor select an alternative proprietary name and submit the alternate name to the Agency for the Division of Medication Error Prevention and Analysis to review. However, in rare instances FMEA may identify plausible strategies that could reduce the risk of medication error of the currently proposed name, and so we may be able to provide the Sponsor with recommendations that reduce or eliminate the potential for error would render the proposed name acceptable.

3 RESULTS

3.1 PROPRIETARY NAME RISK ASSESSMENT

3.1.1 Database and Information Sources

The search identified 18 names as having some similarity to the name Vimpat.

Sixteen of the 18 names were thought to look like Vimpat, which include: Simplet, Nimbex, Zanfel, Zemplar, Vingate, Sernate, Vingel, Vimpo-Zine, Vimax, Urispas, Umi-Pex 30, Viracept, Venspan, and Ramipril. One name, Fempatch, was thought to sound like Vimpat. One name, Vinac, was thought to look and sound similar to Vimpat.

Additionally, the Division of Medication Error Prevention and Analysis did not identify any USAN stems in the name Vimpat as of October 3, 2008.

3.1.2 Expert Panel Discussion

The Expert Panel reviewed the pool of names identified by the Division of Medication Error Prevention and Analysis staff (see section 3.1.1. above), and did not note any additional names thought to have orthographic or phonetic similarity to Vimpat and have the potential for confusion.

DDMAC had no concerns regarding the proposed name from a promotional perspective, and did not offer any additional comments relating to the proposed name.

3.1.3 Safety Evaluator Risk Assessment of Proposed Proprietary Name

Independent searches by the primary Safety Evaluator identified three additional names (Comvax, Relpax, and Compat) thought to look similar to and represent a potential source of drug name confusion.

*** Note: This review contains proprietary and confidential information that should not be released to the public. ***
As such, a total of 21 names were analyzed to determine if the drug names could be confused with Vimpat, and if the drug name confusion would likely result in a medication error.

Failure modes and effects analysis was then applied to determine if the proposed name, Vimpat, could potentially be confused with any of the 21 names and lead to medication errors. This analysis determined that the name similarity between Vimpat and the identified names was unlikely to result in medication errors for all 21 products for reasons described/outlined in Appendices B through I.

4 DISCUSSION

4.1 PROPRIETARY NAME RISK ASSESSMENT

The results of the Proprietary Name Risk Assessment found that the proposed name, Vimpat, has some similarity to other proprietary drug names, but the findings of the FMEA indicate that the proposed name is not vulnerable to name confusion that could lead to medication errors.

The findings of the Proprietary Name Risk Assessment are based upon current understanding of factors that contribute to medication errors involving name confusion. Although we believe the findings of the Risk Assessment to be robust, our findings do have limitations. First, because our assessment involves a limited number of practitioners, it is possible that the analysis did not identify a potentially confusing name. Also, there is some possibility that our Risk Assessment failed to consider a circumstance in which confusion could arise. However, we believe that these limitations are sufficiently minimized by the use of an Expert Panel.

However, our risk assessment also faces limitations beyond the control of the Agency. First, our risk assessment is based on current health care practices and drug product characteristics, future changes to either could increase the vulnerability of the proposed name to confusion. Since these changes cannot be predicted for or accounted for by the current Proprietary Name Risk Assessment process, such changes limit our findings. To help counterbalance this impact, we recommend that the proprietary name be re-submitted for review if approval of the product is delayed beyond 90 days.

5 CONCLUSIONS

The Proprietary Name Risk Assessment findings indicate that the proposed name, Vimpat, is not vulnerable to name confusion that could lead to medication errors. As such, the Division of Medication Error Prevention and Analysis does not object to the use of the proprietary name, Vimpat, for this product. Additionally, DDMAC does not object to the proposed name, Vimpat, from a promotional perspective.

If any of the proposed product characteristics as stated in this review are altered prior to approval of the product; the Division of Medication Error Prevention and Analysis rescinds this Risk Assessment finding, and recommends that the name, labels, and labeling be resubmitted for review. In the event that our Risk Assessment finding is rescinded, the evaluation of the name on resubmission is independent of the previous Risk Assessment, and as such, the conclusions on re-review of the name are subject to change. Additionally, if the product approval is delayed beyond 90 day from the date of this review, the proposed name must be resubmitted for evaluation.
6 RECOMMENDATIONS

6.1 COMMENTS TO THE DIVISION

The Division of Medication Error Prevention and Analysis has no objections to the use of the proprietary name Vimpat for this product.

We would appreciate feedback on the final outcome of this consult. We would be willing to meet with the Division for further discussion, if needed. Please copy the Division of Medication Error Prevention and Analysis on any correspondence to the Applicant pertaining to this issue. If you have further questions or need clarifications, please contact Daniel Brounstein, OSE Project Manager, at 301-796-0674.

6.2 COMMENTS TO THE APPLICANT

Not applicable since the Division will be sending the regulatory action letter with all comments.

7 REFERENCES

1. **Micromedex Integrated Index** ([http://csi.micromedex.com](http://csi.micromedex.com))

   Contains a variety of databases covering pharmacology, therapeutics, toxicology and diagnostics.

2. **Phonetic and Orthographic Computer Analysis (POCA)**

   As part of the name similarity assessment, proposed names are evaluated via a phonetic/orthographic algorithm. The proposed proprietary name is converted into its phonemic representation before it runs through the phonetic algorithm. Likewise, an orthographic algorithm exists which operates in a similar fashion. This is a database which was created for the Division of Medication Error Prevention and Analysis, FDA.

3. **Drug Facts and Comparisons, online version, St. Louis, MO** ([http://factsandcomparisons.com](http://factsandcomparisons.com))

   Drug Facts and Comparisons is a compendium organized by therapeutic course; contains monographs on prescription and OTC drugs, with charts comparing similar products.

4. **AMF Decision Support System [DSS]**

   DSS is a government database used to track individual submissions and assignments in review divisions.

5. **Division of Medication Errors Prevention and Analysis proprietary name consultation requests**

   This is a list of proposed and pending names that is generated by the Division of Medication Error Prevention and Analysis from the Access database/tracking system.

6. **Drugs@FDA** ([http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm](http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm))

   Drugs@FDA contains most of the drug products approved since 1939. The majority of labels, approval letters, reviews, and other information are available for drug products approved from 1998 to the present. Drugs@FDA contains official information about FDA approved brand name, generic drugs, therapeutic biological products, prescription and over-the-counter human drugs and discontinued drugs and "Chemical Type 6" approvals.
7. **Electronic online version of the FDA Orange Book** ([http://www.fda.gov/cder/ob/default.htm](http://www.fda.gov/cder/ob/default.htm))
   Provides a compilation of approved drug products with therapeutic equivalence evaluations.

   Provides information regarding patent and trademarks.

9. **Clinical Pharmacology Online** ([www.clinicalpharmacology-ip.com](http://www.clinicalpharmacology-ip.com))
   Contains full monographs for the most common drugs in clinical use, plus mini monographs covering investigational, less common, combination, nutraceutical and nutritional products. Provides a keyword search engine.

10. **Data provided by Thomson & Thomson's SAEGIS™ Online Service, available at** ([www.thomson-thomson.com](http://www.thomson-thomson.com))
    The Pharma In-Use Search database contains over 400,000 unique pharmaceutical trademarks and trade names that are used in about 50 countries worldwide. The data is provided under license by IMS HEALTH.

11. **Natural Medicines Comprehensive Databases** ([www.naturaldatabase.com](http://www.naturaldatabase.com))
    Contains up-to-date clinical data on the natural medicines, herbal medicines, and dietary supplements used in the western world.

12. **StatRef** ([www.statref.com](http://www.statref.com))
    Contains full-text information from approximately 30 texts. Includes tables and references. Among the database titles are: Handbook of Adverse Drug Interactions, Rudolphs Pediatrics, Basic Clinical Pharmacology and Dictionary of Medical Acronyms Abbreviations.

    List contains all the recognized USAN stems.

14. **Red Book Pharmacy's Fundamental Reference**
    Contains prices and product information for prescription, over-the-counter drugs, medical devices, and accessories.

15. **Lexi-Comp** ([www.lexi.com](http://www.lexi.com))

16. **Medical Abbreviations Book**
    Contains commonly used medical abbreviations and their definitions.

**APPENDICES**

**Appendix A:**

The medication error staff consider the spelling of the name, pronunciation of the name when spoken, and appearance of the name when scripted. The Division of Medication Error Prevention and Analysis also compare the spelling of the proposed proprietary name with the proprietary and established name of existing and proposed drug products because similarly spelled names may have greater likelihood to
sound similar to one another when spoken or look similar to one another when scripted. The medication
error staff also examine the orthographic appearance of the proposed name using a number of different
handwriting samples. Handwritten communication of drug names has a long-standing association with
drug name confusion. Handwriting can cause similarly and dissimilarly spelled drug name pairs to
appear very similar to one another and the similar appearance of drug names when scripted has lead to
medication errors. The medication error staff apply their expertise gained from root-cause analysis of
such medication errors to identify sources of ambiguity within the name that could be introduced when
scripting (e.g. "T" may look like "F," lower case ‘a’ looks like a lower case ‘u,’ etc), along with other
orthographic attributes that determine the overall appearance of the drug name when scripted (see detail
in Table 1 below). Additionally, since verbal communication of medication names is common in clinical
settings, the medication error staff compare the pronunciation of the proposed proprietary name with the
pronunciation of other drug names. If provided, the Division of Medication Error Prevention and
Analysis will consider the Sponsor’s intended pronunciation of the proprietary name. However, because
the Sponsor has little control over how the name will be spoken in practice, we also consider a variety of
pronunciations that could occur in the English language.

Table 1. Criteria used to identify drug names that look- or sound-similar to a proposed proprietary name

<table>
<thead>
<tr>
<th>Type of similarity</th>
<th>Considerations when searching the databases</th>
<th>Potential Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Potential causes of drug name similarity</td>
<td>Attributes examined to identify similar drug names</td>
</tr>
<tr>
<td>Look-alike</td>
<td>Similar spelling</td>
<td>Identical prefix</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Identical infix</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Identical suffix</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Length of the name</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Overlapping product characteristics</td>
</tr>
<tr>
<td></td>
<td>Orthographic similarity</td>
<td>Similar spelling</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Length of the name</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Upstrokes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Downstrokes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cross-stokes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dotted letters</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ambiguity introduced by scripting letters</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Overlapping product characteristics</td>
</tr>
<tr>
<td>Sound-alike</td>
<td>Phonetic similarity</td>
<td>Identical prefix</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Identical infix</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Identical suffix</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Number of syllables</td>
</tr>
</tbody>
</table>

13
<table>
<thead>
<tr>
<th>Stresses</th>
<th>Placement of vowel sounds</th>
<th>Placement of consonant sounds</th>
<th>Overlapping product characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Appendix B:** Names evaluated in our previous review (OSE Review 2007-1610) and the product characteristics have not changed since our previous review

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simplet</td>
<td>Look</td>
</tr>
<tr>
<td>Vinate</td>
<td>Look</td>
</tr>
<tr>
<td>Viracept</td>
<td>Look</td>
</tr>
<tr>
<td>Ramipril</td>
<td>Look</td>
</tr>
<tr>
<td>Fempatch</td>
<td>Sound</td>
</tr>
</tbody>
</table>

**Appendix C:** Name without convincing look-alike and/or sound-alike similarities to Vimapat

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vinpo-Zine</td>
<td>Look</td>
</tr>
</tbody>
</table>

**Appendix D:** Foreign name

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vingel</td>
<td>Look</td>
</tr>
</tbody>
</table>

**Appendix E:** Discontinued Products

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serpate</td>
<td>Look</td>
</tr>
<tr>
<td>Umi-Pex 30</td>
<td>Look</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Umi-Pex 30</td>
<td>Look</td>
</tr>
</tbody>
</table>
**Appendix F:** Non-drug Products

<table>
<thead>
<tr>
<th>Product</th>
<th>Look</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vinae</td>
<td>Look</td>
<td>This is a name for polyvinyl acetate a chemical used in adhesives, binders, sealants, cosmetics and other products.</td>
</tr>
<tr>
<td>Compat</td>
<td>Look</td>
<td>This is the name for a line of enteral delivery systems e.g., feeding pumps, tubing, adapters, containers, and bags.</td>
</tr>
</tbody>
</table>

**Appendix G:** Pending name within the Agency

<table>
<thead>
<tr>
<th>Look</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>The was an alternate name that was not reviewed because the previous name was found acceptable. The product was approved.</td>
</tr>
</tbody>
</table>

**Appendix H:** Products with no numerical overlap in strength and dose.

<table>
<thead>
<tr>
<th>Product name with potential for confusion</th>
<th>Similarity to Vimpat</th>
<th>Strength</th>
<th>Usual Dose (if applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zanfel (polyethylene granules, nonoxynol-9, disodium EDTA, and triethanolamine) Topical Cream Topical Wash Nonprescription product</td>
<td>Look</td>
<td>Not applicable</td>
<td>Apply to affected areas, may repeat in 24 hours.</td>
</tr>
<tr>
<td>Vinmax (Vitamin E, inosine, yohimbe, and other ingredients) Capsule Nonprescription product</td>
<td>Look</td>
<td>Not applicable</td>
<td>1 capsule daily or 30 minutes before sexual activity.</td>
</tr>
</tbody>
</table>

***Note: This review contains proprietary and confidential information that should not be released to the public.***
<table>
<thead>
<tr>
<th>Product name with potential for confusion</th>
<th>Similarity to Vimpat</th>
<th>Strength</th>
<th>Usual Dose (if applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Convax (Haemophilus b PRP and Hepatitis B surface antigen) Injection</td>
<td>Look</td>
<td>7.5 mcg/5 mcg per 0.5 mL</td>
<td>0.5 mL; frequency is determined by vaccination schedule</td>
</tr>
<tr>
<td>Zemplar (Paracalcitol) Capsules and Injection</td>
<td>Look</td>
<td>Capsules: 1 mcg, 2 mcg, and 4 mcg Injection: 2 mcg/mL and 5 mcg/mL</td>
<td>Capsules: 1 mcg or 2 mcg once daily; 2 mcg or 4 mcg three times per week Injection: 0.04 mcg/kg to 0.1 mcg/kg administered no more frequently than every other day at any time during dialysis</td>
</tr>
</tbody>
</table>

**Appendix I:** Names with numerical overlap in strength or dose but with differentiating product characteristics

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Orthographic similarity (“Nim” vs. “Vim”) and (“ex” vs. “at”)</th>
<th>Medication errors unlikely to occur due to orthographic differences between the names in addition to different contexts of use and frequency of administration.</th>
</tr>
</thead>
</table>
| Nimbex (Cisatracurium Besylate) Injection | The products overlap in strength (10 mg/mL). There is a numerical similarity between the doses of the products (10 mg or 15 mg Nimbex vs. 100 mg or 150 mg Vimpat) | *Rationale:*

The upstroke of the letter “b” in Nimbex vs. the downstroke of the letter “p” in Vimpat helps to differentiate the names.

It is unlikely that an order would be written with the product strength. The actual dose would be indicated for both products.

The dosing of Nimbex is weight based whereas Vimpat dosing... |
| **Dose:** 0.15 mg/kg to 0.2 mg/kg, followed by maintenance doses of 0.03 mg/kg or an infusion of 0.5 mcg/kg/min to 10.2 mcg/kg/min. | is not weight based. The context of use of Nimbex is different from that of Vimpat. Nimbex is used primarily in the intraoperative setting whereas Vimpat would more likely be used outside of the operating room. Nimbex is administered intermittently on an “as needed” basis or as a continuous infusion whereas Vimpat would more likely be administered twice daily on a scheduled basis and not as a continuous infusion. |
| Relpax  
| (Eletriptan Hydrobromide) Tablets  
| 20 mg and 40 mg (base)  
| **Indication:** Treatment of migraine  
| **Dose:** 40 mg initially, then repeat in 2 hours if needed.  
|  | Orthographic similarity ("Re" vs. "Vi") and ("pax" vs. "pat")  
|  | There is a numerical similarity between the dose and strength of both products (20 mg dose/strength of Relpax vs. 200 mg dose/strength of Vimpat).  
|  | Overlap could be exacerbated if a trailing zero (e.g., 20.0) is included with Relpax 20 mg  
|  | Orthographic differences between the names in addition to the different frequency of administration minimize the likelihood of medication errors in the usual practice setting.  
| **Rationale:**  
| The upstroke letter "l" in Relpax helps to differentiate the names.  
| In order to obtain a 200 mg dose of Relpax, ten tablets would be required which would likely prompt a call to the prescriber.  
| Usual practice would not typically involve the inclusion of trailing zeros, although medication errors have been linked to this dangerous habit. Numerous campaigns (JCAHO, ISMP, FDA) to eliminate use of trailing zeros when communicating drug information should help to further reduce risk of medication error.  
| Relpax is taken on an as needed basis and the dose may be repeated in 2 hours whereas Vimpat is administered twice daily on a scheduled basis. Relpax has the potential to be prescribed with directions to "use as directed" whereas Vimpat will most likely be ordered with directions to take twice daily.  

***Note: This review contains proprietary and confidential information that should not be released to the public.***
| Urispas (Flavoxate) Tablets 100 mg | Orthographic similarity ("V" vs. "U") and ("pa")
The products have an overlapping 100 mg strength and dose. |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Indication:</em> For relief of dysuria, urgency, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, and urethritis.</td>
<td>Orthographic differences between the names in addition to differences in frequency of administration minimize the likelihood of medication errors in the usual practice setting.</td>
</tr>
<tr>
<td><em>Dose:</em> 1 or 2 tablets three or four times per day</td>
<td><em>Rationale:</em> The letters &quot;ris&quot; in Urispas do not look similar to the letters &quot;im&quot; in Vimpat. Additionally, the upstroke letter &quot;t&quot; in Vimpat helps to differentiate the names. Vimpat is administered twice daily whereas Urispas is administered three or four times per day.</td>
</tr>
</tbody>
</table>

*Appears this way on original*
___ Page(s) Withheld

/  Trade Secret / Confidential (b4)

___ Draft Labeling (b4)

___ Draft Labeling (b5)

___ Deliberative Process (b5)
APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL

APPEARS THIS WAY
ON ORIGINAL
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
-----------------
Loretta Holmes
10/28/2008 03:27:32 PM
DRUG SAFETY OFFICE REVIEWER

Kristina Arnwine
10/28/2008 03:31:21 PM
DRUG SAFETY OFFICE REVIEWER

Denise Toyer
10/28/2008 03:32:56 PM
DRUG SAFETY OFFICE REVIEWER
Date: May 13, 2008

To: Russell Katz, MD, Director
Division of Neurology Products
Bob Rappaport, MD, Director
Division of Anesthesia, Analgesia and Rheumatology Products

Thru: Kellie Taylor, PharmD, MPH, Team Leader
Denise Toyer, PharmD, Deputy Director
Division of Medication Errors and Technical Support

From: Judy Park, PharmD, Safety Evaluator
Division of Medication Errors and Technical Support

Subject: Proprietary Name, Label, and Labeling Review for Vimpat

Drug Name(s): Vimpat (Lacosamide) Tablets. —— and Injection

Application Type/Number: NDA 22-253, NDA 22-254, ———

Applicant: Schwarz Biosciences, Inc.

OSE RCM #: 2007-1610
CONTENTS

EXECUTIVE SUMMARY ............................................................................................................. 3
1 BACKGROUND ....................................................................................................................... 3
   1.1 Introduction .................................................................................................................... 3
   1.2 Product Information ...................................................................................................... 3
2 METHODS AND MATERIALS ............................................................................................... 3
   2.1 Proprietary Name Risk Assessment ............................................................................. 4
   2.2 Label and Labeling Risk Assessment .......................................................................... 9
3 RESULTS ............................................................................................................................... 10
   3.1 Proprietary Name Risk Assessment ............................................................................. 10
   3.2 Labeling and Measuring Device Risk Assessment ....................................................... 11
4 DISCUSSION ......................................................................................................................... 12
   4.1 Proprietary Name ........................................................................................................... 12
   4.2 Labeling and Measuring Device Risk Assessment ....................................................... 12
5 CONCLUSIONS and recommendations ............................................................................. 13
   5.1 Comments To the Division ........................................................................................... 14
   5.2 Comments To The Applicant ......................................................................................... 14
6 REFERENCES ......................................................................................................................... 16
APPENDICES ............................................................................................................................ 18
EXECUTIVE SUMMARY

The Proprietary Name Risk Assessment found that the proposed name, Vimpat, has some similarity to other proprietary and established drug names, but the Failure Modes and Effects Analysis (FMEA) findings indicate that the proposed name does not appear to be vulnerable to name confusion that could lead to medication errors. This finding was consistent with and supported by an independent risk assessment of the proprietary name submitted by the Applicant. Thus, the Division of Medication Error Prevention does not object to the use of the proprietary name, Vimpat, for this product.

The results of the Label and Labeling Risk Assessment found that the presentation of information and design of the proposed insert labeling and measuring devices appear to be vulnerable to confusion that could lead to medication errors. We believe the risks we have identified can be addressed and mitigated prior to drug approval, and provides recommendations in Section 5.2 that aim at reducing the risk of medication errors.

However, if any of the proposed product characteristics as stated in this review are altered prior to approval of the product, we rescind this Risk Assessment finding, and recommends that the name be resubmitted for review. Additionally, if the product approval is delayed beyond 90 days from the date of this review, the proposed name must be resubmitted for evaluation.

1 BACKGROUND

1.1 INTRODUCTION

This consult was written in response to a request from the Division of Neurology to evaluate the proprietary name, insert labeling, and measuring device of Vimpat for its potential to contribute to medication errors. The proposed proprietary name, Vimpat, was evaluated to determine if the name could be potentially confused with other proprietary or established drug names. A forthcoming review (OSE Review #2008-633) will assess the container labels and carton labeling.

1.2 PRODUCT INFORMATION

Vimpat (Lacosamide) is a new molecular entity indicated for partial-onset seizures as adjunctive therapy in patients aged 16 years and older, as well as for management of neuropathic pain associated with diabetic peripheral neuropathy. The recommended dose for partial onset seizures is 100 mg per day twice daily initially, then increased to 200 mg per day to 400 mg per day. The recommended initial dose for diabetic peripheral neuropathic pain is mg per day. When switching from oral to intravenous dose, the initial total daily intravenous dosage should equal the oral total daily dosage and frequency. The parenteral formulation of Vimpat can be administered without further dilution or may be mixed in a compatible diluent and should be administered intravenously over at least minutes. Vimpat will be available in 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg tablets, and 10 mg/mL solution for injection. Only the tablet dosage form is indicated for neuropathic pain. For partial seizure indication, tablets, and injectables are indicated.

2 METHODS AND MATERIALS

This section consists of two sections which describe the methods and materials used by the Division of Medication Error Prevention staff conducting a proprietary name risk assessment (see 2.1 Proprietary Name Risk Assessment) and labeling, and/or packaging risk assessment (see 2.2 Insert Label Risk Assessment). The primary focus for both of the assessments is to identify and remedy potential sources
of medication error prior to drug approval. The Division of Medication Error Prevention defines a medication error as any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer. 1

2.1 PROPRIETARY NAME RISK ASSESSMENT

FDA’s Proprietary Name Risk Assessment considers the potential for confusion between the proposed proprietary name, Vimpat, and the proprietary and established names of drug products existing in the marketplace and those pending IND, NDA, and ANDA products currently under review by the Agency.

For the proprietary name, Vimpat, the Division of Medication Error Prevention staff search a standard set of databases and information sources to identify names with orthographic and phonetic similarity (see Sections 2.1.1 for detail) and held an CDER Expert Panel discussion to gather professional opinions on the safety of the proposed proprietary name (see 2.1.1.2). We also conduct internal CDER prescription analysis studies (see 2.1.2), and, when provided, external prescription analysis studies results are considered and incorporated into the overall risk assessment (see detail 2.1.4).

The Safety Evaluator assigned to the Proprietary Name Risk Assessment is responsible for considering the collective findings, and provides an overall risk assessment of the proposed proprietary name (see detail 2.1.4). The overall risk assessment is based on the findings of a Failure Modes and Effects Analysis (FMEA) of the proprietary name, and is focused on the avoidance of medication errors. FMEA is a systematic tool for evaluating a process and identifying where and how it might fail. 2 FMEA is used to analyze whether the drug names identified with look- or sound-alike similarity to the proposed name could cause confusion that subsequently leads to medication errors in the clinical setting. We use the clinical expertise of the Medication Error Prevention staff to anticipate the conditions of the clinical setting that the product is likely to be used in based on the characteristics of the proposed product.

In addition, the product characteristics provide the context for the verbal and written communication of the drug names and can interact with the orthographic and phonetic attributes of the names to increase the risk of confusion when there is overlap, or, in some instances, decrease the risk of confusion by helping to differentiate the products through dissimilarity. As such, the Staff consider the product characteristics associated with the proposed drug throughout the risk assessment, since the product characteristics of the proposed may provide a context for communication of the drug name and ultimately determine the use of the product in the usual clinical practice setting.

Typical product characteristics considered when identifying drug names that could potentially be confused with the proposed drug name include, but are not limited to established name of the proposed product, the proposed indication, dosage form, route of administration, strength, unit of measure, dosage units, recommended dose, typical quantity or volume, frequency of administration, product packaging, storage conditions, patient population, and prescriber population. Because drug name confusion can occur at any point in the medication use process, we consider the potential for confusion throughout the entire U.S. medication use process, including drug procurement, prescribing and ordering, dispensing, administration, and monitoring the impact of the medication. 3


2.1.1 Search Criteria

The Medication Error Prevention Staff consider the spelling of the name, pronunciation of the name when spoken, and appearance of the name when scripted as outlined in Appendix A.

For this review, particular consideration was given to drug names beginning with the letter ‘V’ when searching to identify potentially similar drug names, as 75% of the confused drug names reported by the USP-ISMP Medication Error Reporting Program involve pairs beginning with the same letter.45

To identify drug names that may look similar to Vimpat, the Staff also consider the orthographic appearance of the name on lined and unlined orders. Specific attributes taken into consideration include the length of the name (6 letters), upstrokes (2, capital letter ‘V’ and lower case letter ‘v’), downstroke (lower case letter ‘p’), cross-strokes (lower case letter ‘t’), and dotted letters (one, lower case letter ‘i’). Additionally, several letters in Vimpat may be vulnerable to ambiguity when scripted, including the letter ‘V’ may appear as ‘Y,’ ‘U,’ or ‘L’; and a lower case ‘v’ appear as a lower case ‘r,’ ‘u,’ or ‘x’. As such, the Staff also consider these alternate appearances when identifying drug names that may look similar to Vimpat.

When searching to identify potential names that may look or sound similar to Vimpat, the Medication Error Prevention Staff search for names with similar number of syllables (2), and placement of vowel and consonant sounds. The Applicant’s intended pronunciation of the proprietary name (VIM-pat) was also taken into consideration.

The Staff also consider the product characteristics associated with the proposed drug throughout the identification of similar drug names, since the product characteristics of the proposed drug ultimately determine the use of the product in the clinical practice setting. For this review, the Medication Error Prevention Staff were provided with the following information about the proposed product: the proposed proprietary name (Vimpat), the established name (Lacosamide), proposed indications (partial onset seizures and diabetic peripheral neuropathic pain), strength (50 mg, 100 mg, 150 mg, 200 mg, 250 mg and 300 mg tablets; 10 mg/mL solution for injection), dose (200 mg/day to 400 mg/day for partial onset seizures, frequency of administration (twice a day), route (oral and intravenous) and dosage form of the product (tablet, — and injection). Appendix A provides a more detailed listing of the product characteristics the Medication Error Prevention Staff general take into consideration.

Lastly, the Medication Error Prevention Staff also consider the potential for the proposed name to inadvertently function as a source of error for reasons other than name confusion. Post-marketing experience has demonstrated that proprietary names (or components of the proprietary name) can be a source of error in a variety of ways. As such, these broader safety implications of the name are considered and evaluated throughout this assessment and the Medication Error Prevention Staff provide additional comments related to the safety of the proposed name or product based on their professional experience with medication errors.

2.1.1.1 Database and information sources

The proposed proprietary name, Vimpat, was provided to the Division of Medication Error Prevention staff to conduct a search of the internet, several standard published drug product reference texts, and FDA

databases to identify existing and proposed drug names that may sound-alike or look-alike to Vimpat, using the criteria outlined in 2.1.1. A standard description of the databases used in the searches is provided in Section 7. To complement the process, the Medication Error Prevention Staff use a computerized method of identifying phonetic and orthographic similarity between medication names. The program, Phonetic and Orthographic Computer Analysis (POCA), uses complex algorithms to select a list of names from a database that have some similarity (phonetic, orthographic, or both) to the trademark being evaluated. Lastly, the Medication Error Prevention Staff review the USAN stem list to determine if any USAN stems are present within the proprietary name. The findings of the individual Safety Evaluators were then pooled and presented to the Expert Panel.

2.1.1.2 CDER Expert Panel Discussion

An Expert Panel Discussion is held by the Division of Medication Error Prevention to gather CDER professional opinions on the safety of the product and the proprietary name, Vimpat. Potential concerns regarding drug marketing and promotion related to the proposed names are also discussed. This group is composed of The Division of Medication Error Prevention Staff and representatives from the Division of Drug Marketing, Advertising, and Communications (DDMAC).

The pooled results of the Medication Error Prevention staff were presented to the Expert Panel for consideration. Based on the clinical and professional experiences of the Expert Panel members, the Panel may recommend the addition of names, additional searches by the Safety Evaluator to supplement the pooled results, or general advice to consider when reviewing the proposed proprietary name.

2.1.2 CDER Prescription analysis studies

Three separate studies are conducted within the Centers of the FDA for the proposed proprietary name to determine the degree of confusion of Vimpat with marketed U.S. drug names (proprietary and established) due to similarity in visual appearance with handwritten prescriptions or verbal pronunciation of the drug name. The studies employ a total of 123 healthcare professionals (pharmacists, physicians, and nurses), and attempts to simulate the prescription ordering process. The results are used by the Safety Evaluator to identify any orthographic or phonetic vulnerability of the proposed name to be misinterpreted by healthcare practitioners.

In order to evaluate the potential for misinterpretation of Vimpat in handwriting and verbal communication of the name, inpatient medication orders and outpatient prescriptions are written, each consisting of a combination of marketed and unapproved drug products, including the proposed name. These prescriptions are optically scanned and one prescription is delivered to a random sample of 123 participating health professionals via e-mail. In addition, a verbal prescription is recorded on voice mail. The voice mail messages are then sent to a random sample of the participating health professionals for their interpretations and review. After receiving either the written or verbal prescription orders, the participants send their interpretations of the orders via e-mail to the Division of Medication Error Prevention staff.

Figure 1. Vimpat Study (conducted on August 10, 2007)

<table>
<thead>
<tr>
<th>HANDWRITTEN PRESCRIPTION AND MEDICATION ORDER</th>
<th>VERBAL PRESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Outpatient Prescription:</strong></td>
<td>Vimpat 100mg #30</td>
</tr>
<tr>
<td>Vimpat 100mg</td>
<td>Take one tablet by mouth</td>
</tr>
<tr>
<td>#30</td>
<td>twice a day</td>
</tr>
<tr>
<td>1st of May 2009</td>
<td></td>
</tr>
</tbody>
</table>
2.1.3 **External Proprietary Name Risk Assessment**

For this product, the Applicant submitted two independent risk assessments of the proposed proprietary name conducted by [redacted]. We conducted an independent analysis and evaluation of the data provided, and respond to the overall findings of the assessment. When the external proprietary name risk assessment identifies potentially confusing names that were not captured in the Medication Error Prevention Staff’s database searches or in the Expert Panel Discussion, these names are included in the Safety Evaluator’s Risk Assessment and analyzed independently by the Safety Evaluator to determine if the potentially confusing name could lead to medication errors in usual practice settings.

After the Safety Evaluator has determined the overall risk assessment of the proposed name, the Safety Evaluator compares the findings of their overall risk assessment with the findings of the proprietary name risk assessment submitted by the Applicant. The Safety Evaluator then determines whether our risk assessment concurs or differs with the findings. When the proprietary name risk assessments differ, we provide a detailed explanation of these differences.

2.1.4 **Safety Evaluator Risk Assessment of the Proposed Proprietary Name**

Based on the criteria set forth in Section 2.1.1, the Safety Evaluator Risk Assessment applies their individual expertise gained from evaluating medication errors reported to FDA to conduct a Failure Modes and Effects Analysis and provide an overall risk of name confusion. Failure Mode and Effects Analysis (FMEA) is a systematic tool for evaluating a process and identifying where and how it might fail. When applying FMEA to assess the risk of a proposed proprietary name, we seek to evaluate the potential for a proposed name to be confused with another drug name as a result of the name confusion and cause errors to occur in the medication use system. FMEA capitalizes on the predictable and preventable nature of medication errors associated with drug name confusion. FMEA allows the Agency to identify the potential for medication errors due to look- or sound-alike drug names prior to approval, where actions to overcome these issues are easier and more effective then remedies available in the post-approval phase.

In order to perform an FMEA of the proposed name, the Safety Evaluator must analyze the use of the product at all points in the medication use system. Because the proposed product is not yet marketed, the Safety Evaluator anticipates the use of the product in the usual practice settings by considering the clinical and product characteristics listed in Appendix A. The Safety Evaluator then analyzes the proposed proprietary name in the context of the usual practice setting and works to identify potential failure modes and the effects associated with the failure modes.

In the initial stage of the Risk Assessment, the Safety Evaluator compares the proposed proprietary name to all of the names gathered from the above searches, expert panel evaluation, and studies, and identifies potential failure modes by asking: “Is the name Vimpat, convincingly similar to another drug name, which may cause practitioners to become confused at any point in the usual practice setting?” An affirmative answer indicates a failure mode and represents a potential for Vimpat to be confused with another proprietary or established drug name because of look- or sound-alike similarity. If the answer to the question is no, the Safety Evaluator is not convinced that the names possess similarity that would cause confusion at any point in the medication use system and the name is eliminated from further review.

---

In the second stage of the Risk Assessment, all potential failure modes are evaluated to determine the likely effect of the drug name confusion, by asking "Could the confusion of the drug names conceivably result in medication errors in the usual practice setting?" The answer to this question is a central component of the Safety Evaluator's overall risk assessment of the proprietary name. If the Safety Evaluator determines through FMEA that the name similarity would ultimately not be a source of medication errors in the usual practice setting, the name is eliminated from further analysis. However, if the Safety Evaluator determines through FMEA that the name similarity could ultimately cause medication errors in the usual practice setting, the Safety Evaluator will then recommend that an alternate proprietary name be used. In rare instances, the FMEA findings may provide other risk-reduction strategies, such as product reformulation to avoid an overlap in strength or an alternate modifier designation may be recommended as a means of reducing the risk of medication errors resulting from drug name confusion.

We will object to the use of proposed proprietary name when the one or more of the following conditions are identified in the Safety Evaluator's Risk Assessment:

1. DDMAC finds the proposed proprietary name misleading from a promotional perspective, and the review Division concurs with DDMAC's findings. The Federal Food, Drug, and Cosmetic Act provides that labeling or advertising can misbrand a product if misleading representations are made or suggested by statement, word, design, device, or any combination thereof, whether through a trade name or otherwise. [21 U.S.C 321(n); see also 21 U.S.C. 352(a) & (n)].

2. The Division of Medication Error Prevention identifies that the proposed proprietary name is misleading because of similarity in spelling or pronunciation to another proprietary or established name of a different drug or ingredient [CFR 201.10(C)(5)].

3. FMEA identifies potential for confusion between the proposed proprietary name and other proprietary or established drug names, and demonstrates that medication errors are likely to result from the drug name confusion under the conditions of usual clinical practice.

4. The proposed proprietary name contains an USAN stem, particularly in a manner that is contradictory to the USAN Council's definition.

5. The Division of Medication Error Prevention Staff identify a potential source of medication error within the proposed proprietary name. The proprietary name may be misleading, or inadvertently introduce ambiguity and confusion that leads to errors. Such errors may not necessarily involve confusion between the proposed drug another drug product.

In the event that we object to the use of the proposed proprietary name, based upon the potential for confusion with another proposed (but not yet approved) proprietary name, we will provide a contingency objection based on the date of approval: whichever product is awarded approval first has the right to the use the name, while we will recommend that the second product to reach approval seek an alternative name.

If none of these conditions are met, then we will not object to the use of the proprietary name. If any of these conditions are met, then we will object to the use of the proprietary name. The threshold set for objection to the proposed proprietary name may seem low to the Applicant; however, the safety concerns set forth in criteria 1 through 5 are supported either by FDA Regulation or by external healthcare authorities, including the IOM, WHO, JCAHO, and ISMP, have examined medication errors resulting from look- or sound-alike drug names and called for Regulatory Authorities to address the issue prior to approval.

Furthermore, we contend that the threshold set for the Proprietary Name Risk Assessment is reasonable because proprietary drug name confusion is a predictable and preventable source of medication error that, in many instances, can be identified and remedied prior to approval to avoid patient harm.
Additionally, post-marketing experience has demonstrated that medication errors resulting from drug name confusion are notoriously difficult to remedy post-approval. Educational efforts and so on are low-leverage strategies that have proven to have limited effectiveness at alleviating the medication errors involving drug name confusion. Higher-leverage strategies, such as drug name changes, have been undertaken in the past; but at great financial cost to the Applicant, and at the expense of the public welfare, not to mention the Agency’s credibility as the authority responsible for the approving the error-prone proprietary name. Moreover, even after Applicant’s have changed a product’s proprietary name in the post-approval phase, it is difficult to eradicate the original proprietary name from practitioner’s vocabulary, and as such, the Agency has continued to receive reports of drug name confusion long after a name change in some instances. Therefore, we believe that post-approval efforts at reducing name confusion errors should be reserved for those cases in which the potential for name confusion could not be predicted prior to approval (see section 4: “Discussion” for limitations of the process).

If we object to a proposed proprietary name on the basis that drug name confusion could lead to medication errors, the FMEA process is used to identify strategies to reduce the risk of medication errors. We are likely to recommend that the Applicant select an alternative proprietary name and submit the alternate name to the Agency for us to review. However, in rare instances FMEA may identify plausible strategies that could reduce the risk of medication error of the currently proposed name, and so we may be able to provide the Applicant with recommendations that reduce or eliminate the potential for error would render the proposed name acceptable.

2.2 LABEL AND LABELING RISK ASSESSMENT

The label and labeling of a drug product are the primary means by which practitioners and patients (depending on configuration) interact with the pharmaceutical product. The container labels and carton labeling communicate critical information including proprietary and established name, strength, form, container quantity, expiration, and so on. The insert labeling is intended to communicate to practitioners all information relevant to the approved uses of the drug, including the correct dosing and administration.

Given the critical role that the label and labeling has in the safe use of drug products, it is not surprising that 33 percent of medication errors reported to the USP-ISMP Medication Error Reporting Program may be attributed to the packaging and labeling of drug products, including 30 percent of fatal errors. Because our staff analyze reported misuse of drugs, our staff are able to use this experience to identify potential errors with all medication similarly packaged, labeled or prescribed. We use FMEA and the principles of human factors to identify potential sources of error with the proposed product labels and insert labeling, and provided recommendations that aim at reducing the risk of medication errors.

For this product the Applicant submitted on September 28, 2007 the following labeling and measuring device for our review (see Appendix E for images):

- Prescribing Information (no image)  
- Patient Information (no image)

A forthcoming review (OSE Review #2008-633) will assess the container labels and carton labeling for Vimpat tablets and injectable.

3 RESULTS

3.1 PROPRIETARY NAME RISK ASSESSMENT

3.1.1 Data base and information sources

We conducted a search of the internet, several standard published databases and information sources (see Section 7 References) for existing drug names which sound-alike or look-alike to Vimpat to a degree where potential confusion between drug names could occur and result in medication errors in the usual clinical practice settings. In total, seven names were identified as having some similarity to the name Vimpat.

Four of the seven names were thought to look like Vimpat, which include: Vinar, Campath, Simplet, and Semprex-D. Fempatch was thought to sound like Vimpat and two names, ----, and Impact, were thought to look and sound similar to Vimpat. No USAN stems are present within the proposed name.

3.1.2 Expert panel discussion

The Expert Panel also noted that despite orthographic similarity of the letter 'V' with the letters 'Z', 'N', 'L', and 'R' in some handwriting samples, no names beginning with those letters were included in the pool. The Expert Panel recommended that independent searches consider the potential for confusion with drug names beginning with these letters.

DDMAC had no concerns regarding the proposed name from a promotional perspective, and did not offer any additional comments relating to the proposed name.

3.1.3 CDER Prescription analysis studies

A total of 30 practitioners responded, but none of the responses overlapped with any existing or proposed drug names. About 60% of the participants (n=18) interpreted the name correctly as "Vimpat," with correct interpretation occurring more frequently in the written studies. The remainder of the responses misinterpreted the drug name. Four respondents in the verbal prescription study each misinterpreted Vimpat as Zymtec, Zimpack, Zynpak, and Zin Pac. In the written prescription studies, the letter 'a' was misinterpreted as an 'i' by another respondent. The ending 'at' was misinterpreted as 'art' by five respondents and 'ert' by one respondent. See Appendix B for the complete listing of interpretations from the verbal and written prescription studies.

3.1.4 External Name studies

In the two proposed name risk assessments submitted by the Applicant, the study identified and evaluated a total of 8 drug names thought to have some potential for confusion with the name Vimpat, and the study identified and evaluated a total of 28 names thought to have some potential for confusion with the name Vimpat. However, both studies identified the names Virecept and Viroptic in their results, therefore the total number of names from both studies excluding duplications is 34.

Thirty of the total 34 names were not previously identified in our searches, the Expert Panel Discussion, or FDA prescription studies. Five names (vinblastine, Z-pack, enalapril, Actiq, and Symbicort) were thought by practitioners to sound similar to Vimpat. Three names (Viroptic, Zovirax, and ranipril) were thought by practitioners to look similar to Vimpat. Two names (Virecept and vincristine) were thought by practitioners to look and sound similar to Vimpat. The remaining 20 names were identified by the

---

*** This review contains proprietary and confidential information that should not be released to the public.
3.1.5 Safety evaluator risk assessment

In the independent searches by the primary Safety Evaluator, careful evaluation was afforded to drug names beginning with the letters 'Z', 'N', 'L', and 'R' in accordance with the Expert Panel's recommendations, but no additional drug names beginning with these letters were thought to have the potential for confusion with Vimpat. As such, a total of 37 names were analyzed to determine if the drug names could be confused with Vimpat and if the drug name confusion would likely result in a medication error.

All of the identified names were determined to have some orthographic and/or phonetic similarity to Vimpat, and thus determined to present some risk for confusion. Failure modes and effects analysis (FMEA) was then applied to determine if the proposed name, Vimpat, could potentially be confused with any of the 37 names and lead to medication error.

This analysis determined that the name similarity between Vimpat and the identified names was unlikely to result in medication errors. One name, ____________, was not considered further because it was a proposed name for an ____________ product which we objected to _____________. The product was approved as a different proprietary name, ____________. For 31 of the names identified, FMEA determined that medication errors were unlikely because the products do not overlap in strength or dosage with Vimpat and have minimal orthographic and/or visual similarity to Vimpat (Appendix C). Five names (Viracept, Z-Pak, Zovirax, Viread, and Vamate) had some overlap with Vimpat in either dosage or strength, but analysis of the failure mode did not determine the effect of this similarity to result in medication errors in the usual practice setting (see Appendix D).

3.2 LABELING ANE

---

*** This review contains proprietary and confidential information that should not be released to the public.
4 DISCUSSION

4.1 PROPRIETARY NAME

The results of the Proprietary Name Risk Assessment found that the proposed name, Vimpat, has some similarity to other proprietary and established drug names, but the findings of the FMEA indicates that the proposed name does not appear to be vulnerable to name confusion that could lead to medication errors. This finding was consistent with and supported by an independent risk assessment of the proprietary name submitted by the Applicant. Thus, the Division of Medication Error Prevention has no objections to the use of the proprietary name, Vimpat for this product.

4.2 LABELING AND _______ RISK ASSESSMENT

The results of the Label and Labeling Risk Assessment found that the presentation of information and design of the proposed insert labeling and ________ appears to be vulnerable to confusion that could lead to medication errors.
5 CONCLUSIONS AND RECOMMENDATIONS

The Proprietary Name Risk Assessment findings indicate that the proposed name, Vimpat, does not appear to be vulnerable to name confusion that could lead to medication errors. This finding was consistent with and supported by an independent risk assessments of the proprietary name submitted by the Applicant. As such, the Division of Medication Error Prevention does not object to the use of the proprietary name, Vimpat, for this product.

The Labeling and Measuring Device Risk Assessment findings indicate that the presentation of information and design of the proposed carton and container labels introduces vulnerability to confusion that could lead to medication errors. We believe the risks we have identified can be addressed and
mitigated prior to drug approval, and provides recommendations in Section 5.2 that aim at reducing the risk of medication errors.

5.1 COMMENTS TO THE DIVISION

The Division of Medication Error Prevention does not object to the use of the proprietary name, Vimpat, for this product. However, if any of the proposed product characteristics as stated in this review are altered prior to approval of the product, we rescind this Risk Assessment finding, and recommend that the name be resubmitted for review. Additionally, if the product approval is delayed beyond 90 days from the date of this review, the proposed name must be resubmitted for evaluation.

Based upon our assessment of the proprietary name, labeling and we have identified areas needed of improvement. We have provided recommendations in Section 5.2 and request this information be forwarded to the Applicant.

We would appreciate feedback on the final outcome of this review. Please copy us on any communication to the Applicant with regard to this review. We would be willing to meet with the Division for further discussion, if needed. If you have further questions or need clarifications, please contact Daniel Brounstein, Project Manager, at 301-796-0674.

5.2 COMMENTS TO THE APPLICANT

The Division of Medication Error Prevention does not object to the use of the proprietary name, Vimpat, for this product.

Overall, our Risk Assessment is limited by our current understanding of medication errors and causality. The successful application of Failure Modes and Effect Analysis depends upon the learning gained from a spontaneous reporting program. It is quite possible that our understanding of medication error causality would benefit from unreported medication errors; and, that this understanding could have enabled the Staff to identify vulnerability in the proposed name, packaging, and labeling that was not identified in this assessment. To help minimize this limitation in future assessments, we encourage the Applicant to provide the Agency with medication error reports involving their marketed drug products regardless of adverse event severity.

5.2.1 Proprietary Name

1. If any of the proposed product characteristics as stated in this review are altered prior to approval of the product, the Division of Medication Error Prevention rescinds this Risk Assessment finding, and recommends that the name be resubmitted for review.
Page(s) Withheld

/  

Trade Secret / Confidential (b4)

Draft Labeling (b4)

Draft Labeling (b5)

Deliberative Process (b5)
6 REFERENCES

1. **Micromedex Integrated Index** (http://weblern/)
   Contains a variety of databases covering pharmacology, therapeutics, toxicology and diagnostics.

2. **Phonetic and Orthographic Computer Analysis (POCA)**
   As part of the name similarity assessment, proposed names are evaluated via a phonetic/orthographic algorithm. The proposed proprietary name is converted into its phonemic representation before it runs through the phonetic algorithm. Likewise, an orthographic algorithm exists which operates in a similar fashion. This is a database which was created for the Division of Medication Error Prevention, FDA.

3. **Drug Facts and Comparisons, online version, St. Louis, MO** (http://weblern/)
   Drug Facts and Comparisons is a compendium organized by therapeutic Course; contains monographs on prescription and OTC drugs, with charts comparing similar products.

4. **AMF Decision Support System [DSS]**
   DSS is a government database used to track individual submissions and assignments in review divisions.

5. **Division of Medication Errors and Technical Support proprietary name consultation requests**
   This is a list of proposed and pending names that is generated by the Division of Medication Error Prevention from the Access database/tracking system.

6. **Drugs@FDA** (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm)
   Drugs@FDA contains most of the drug products approved since 1939. The majority of labels, approval letters, reviews, and other information are available for drug products approved from 1998 to the present. Drugs@FDA contains official information about FDA approved brand name and generic drugs and therapeutic biological products; prescription and over-the-counter human drugs and therapeutic biologicals, discontinued drugs and “Chemical Type G” approvals.

7. **Electronic online version of the FDA Orange Book** (http://www.fda.gov/cder/ob/default.htm)
   Provides a compilation of approved drug products with therapeutic equivalence evaluations.

   Provides information regarding patent and trademarks.

9. **Clinical Pharmacology Online** (http://weblern/)
   Contains full monographs for the most common drugs in clinical use, plus mini monographs covering investigational, less common, combination, nutraceutical and nutritional products. Provides a keyword search engine.

The Pharma In-Use Search database contains over 400,000 unique pharmaceutical trademarks and tradenames that are used in about 50 countries worldwide. The data is provided under license by IMS HEALTH.

11. Natural Medicines Comprehensive Databases (http://weblern/)

Contains up-to-date clinical data on the natural medicines, herbal medicines, and dietary supplements used in the western world.

12. StatRef (http://weblern/)

Contains full-text information from approximately 30 texts. Includes tables and references. Among the database titles are: Handbook of Adverse Drug Interactions, Rudolph's Pediatrics, Basic Clinical Pharmacology and Dictionary of Medical Acronyms Abbreviations.


List contains all the recognized USAN stems.

14. Red Book Pharmacy's Fundamental Reference

Contains prices and product information for prescription, over-the-counter drugs, medical devices, and accessories.

15. Lexi-Comp (www.pharmacist.com)


16. Medical Abbreviations Book

Contains commonly used medical abbreviations and their definitions.
APPENDICES

Appendix A:

The Division of Medication Error Prevention Staff consider the spelling of the name, pronunciation of the name when spoken, and appearance of the name when scripted. We also compare the spelling of the proposed proprietary name with the proprietary and established name of existing and proposed drug products because similarly spelled names may have greater likelihood to sound similar to one another when spoken or look similar to one another when scripted. The Medication Error Prevention Staff also examine the orthographic appearance of the proposed name using a number of different handwriting samples. Handwritten communication of drug names has a long-standing association with drug name confusion. Handwriting can cause similarly and dissimilarly spelled drug name pairs to appear very similar to one another and the similar appearance of drug names when scripted has lead to medication errors. The Medication Error Prevention Staff apply their expertise gained from root-cause analysis of such medication errors to identify sources of ambiguity within the name that could be introduced when scripting (i.e. “T” may look like “F,” lower case ‘a’ looks like a lower case ‘u,’ etc), along with other orthographic attributes that determine the overall appearance of the drug name when scripted (see detail in Table 1 below). Additionally, since verbal communication of medication names is common in clinical settings, the Medication Error Prevention Staff compare the pronunciation of the proposed proprietary name with the pronunciation of other drug names. If provided, we will consider the Applicant’s intended pronunciation of the proprietary name. However, because the Applicant has little control over how the name will be spoken in practice, we also consider a variety of pronunciations that could occur in the English language.

<table>
<thead>
<tr>
<th>Type of similarity</th>
<th>Considerations when searching the databases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potential causes of drug name similarity</td>
<td>Attributes examined to identify similar drug names</td>
</tr>
<tr>
<td>Look-alike</td>
<td></td>
</tr>
<tr>
<td>Similar spelling</td>
<td>Identical prefix</td>
</tr>
<tr>
<td></td>
<td>Identical infix</td>
</tr>
<tr>
<td></td>
<td>Identical suffix</td>
</tr>
<tr>
<td></td>
<td>Length of the name</td>
</tr>
<tr>
<td></td>
<td>Overlapping product characteristics</td>
</tr>
<tr>
<td>Orthographic similarity</td>
<td>Similar spelling</td>
</tr>
<tr>
<td></td>
<td>Length of the name</td>
</tr>
<tr>
<td></td>
<td>Upstokes</td>
</tr>
<tr>
<td></td>
<td>Downstrokes</td>
</tr>
<tr>
<td></td>
<td>Cross-stokes</td>
</tr>
</tbody>
</table>

- Names may appear similar in print or electronic media and lead to drug name confusion in printed or electronic communication
- Names may look similar when scripted and lead to drug name confusion in written communication
- Names may look similar when scripted, and lead to drug name confusion in written communication
| Sound-alike | Phonetic similarity | Dotted letters  
|            |                   | Ambiguity introduced by scripting letters  
|            |                   | Overlapping product characteristics  
|            |                   |  
|            |                   | Identical prefix  
|            |                   | Identical infix  
|            |                   | Identical suffix  
|            |                   | Number of syllables  
|            |                   | Stresses  
|            |                   | Placement of vowel sounds  
|            |                   | Placement of consonant sounds  
|            |                   | Overlapping product characteristics  
|            |                   |  
|            |                   | • Names may sound similar when pronounced and lead to drug name confusion in verbal communication  

**Appears this way on original**
### Appendix B:

CDER Prescription Study Responses

<table>
<thead>
<tr>
<th>Outpatient Prescription</th>
<th>Value Prescription</th>
<th>Inpatient Medication Order</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vimpat</td>
<td>Zimtec</td>
<td>Vimpat</td>
</tr>
<tr>
<td>Vimpat</td>
<td>Zynpak</td>
<td>Vimpit</td>
</tr>
<tr>
<td>Vimpat</td>
<td>Zin Pac</td>
<td>Vimpat</td>
</tr>
<tr>
<td>Vimpat</td>
<td>Zimpack</td>
<td>Vimpert</td>
</tr>
<tr>
<td>vimpat</td>
<td></td>
<td>Vimpat</td>
</tr>
<tr>
<td>Vimpat</td>
<td></td>
<td>Vimpat</td>
</tr>
<tr>
<td>Vimpat</td>
<td></td>
<td>Vimpart</td>
</tr>
<tr>
<td>Vimpat</td>
<td></td>
<td>Vimpat</td>
</tr>
<tr>
<td>Vimpat</td>
<td></td>
<td>Vimpat</td>
</tr>
<tr>
<td>Vimpat</td>
<td></td>
<td>Vimpat</td>
</tr>
<tr>
<td>Vimpat</td>
<td></td>
<td>Vimpart</td>
</tr>
<tr>
<td>Vimpat</td>
<td></td>
<td>Vimpat</td>
</tr>
<tr>
<td>Vimpat</td>
<td></td>
<td>Vimpat</td>
</tr>
<tr>
<td>Vimpat</td>
<td></td>
<td>Vimpart</td>
</tr>
</tbody>
</table>
### Appendix C: Products with no overlap in strength and dose.

<table>
<thead>
<tr>
<th>Product name with potential for confusion</th>
<th>Similarity to Proposed Proprietary Name</th>
<th>Strength</th>
<th>Usual Dose (if applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vimpat (Lacosamide)</td>
<td>Tablets: 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg; Injection: 10 mg/mL.</td>
<td>Partial onset seizure: 200 mg/day to 400 mg/day (twice daily dosing); Maximum dose — — mg/day</td>
<td>Diabetic peripheral neuropathic pain:</td>
</tr>
<tr>
<td>Vimar (Over-the-Counter)</td>
<td>Look</td>
<td>Multivitamin combination</td>
<td>Information not available</td>
</tr>
<tr>
<td>Campath</td>
<td>Look</td>
<td>30 mg/mL</td>
<td>30 mg/day</td>
</tr>
<tr>
<td>Simplet (Acetaminophen/Chlorpheniramine/Pseudoephedrine) (Over-the-Counter)</td>
<td>Look</td>
<td>650 mg/4 mg/60 mg</td>
<td>1 tablet every 4-6 hours</td>
</tr>
<tr>
<td>Semprex-D</td>
<td>Look</td>
<td>8 mg/60 mg</td>
<td>1 capsule every 4-6 hours</td>
</tr>
<tr>
<td>Viropic</td>
<td>Look</td>
<td>1%</td>
<td>1 drop every 2 hours</td>
</tr>
<tr>
<td>Ramipril</td>
<td>Look</td>
<td>1.25 mg, 2.5 mg, 5 mg, 10 mg</td>
<td>2.5 mg/day to 20 mg/day administered as a single dose or in two equally divided doses</td>
</tr>
<tr>
<td>Fempatch (Estradiol) (Discontinued)</td>
<td>Sound</td>
<td>0.025 mg/24 hours</td>
<td>1 patch weekly</td>
</tr>
<tr>
<td>Vinblastine</td>
<td>Sound</td>
<td>10 mg/vial; 1 mg/mL</td>
<td>3.7 to 7.4 mg/m²</td>
</tr>
<tr>
<td>Enalapril/Prinivil</td>
<td>Sound</td>
<td>Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg; Injectable: 1.25 mg/mL</td>
<td>10 mg/day to 40 mg/day administered in a single dose or 2 divided doses</td>
</tr>
<tr>
<td>Symblyx (Fluoxetine/Olanzapine)</td>
<td>Sound</td>
<td>25 mg/3 mg; 25 mg/6 mg; 25 mg/12 mg; 50 mg/6 mg; 50 mg/12 mg</td>
<td>6 mg/25 mg once daily in the evening</td>
</tr>
<tr>
<td>Actiq (Fentanyl Citrate)</td>
<td>Sound</td>
<td>0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1.2 mg, 1.6 mg</td>
<td>Individualized to patient</td>
</tr>
<tr>
<td>Vincristine</td>
<td>Look/Sound</td>
<td>1 mg/mL</td>
<td>1.4 mg/m²</td>
</tr>
<tr>
<td>Brand Name</td>
<td>Formulation</td>
<td>Dosage</td>
<td>Administration and Information</td>
</tr>
<tr>
<td>------------</td>
<td>-------------</td>
<td>--------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Zymar</td>
<td>Look/Sound</td>
<td>0.3%</td>
<td>Days 1 and 2: Instill 1 drop in affected eye(s) every 2 hours while awake, up to 8 times/day. Days 3 through 7: Instill 1 drop up to 4 times/day while awake.</td>
</tr>
<tr>
<td>Compak</td>
<td>Look/Sound</td>
<td>Gastrostomy tube; Top fill feeding containers: 28 fl</td>
<td>Information not available</td>
</tr>
<tr>
<td>Visapen</td>
<td>Look/Sound</td>
<td>Cold storage solution for organs</td>
<td>Detailed preparation instructions</td>
</tr>
<tr>
<td>Vi-atro (Diphenoxylate/Atropine)</td>
<td>Look/Sound</td>
<td>2.5 mg/0.025 mg</td>
<td>2 tablets three to four times a day</td>
</tr>
<tr>
<td>Vibal (Vitamin B12) (Discontinued)</td>
<td>Look/Sound</td>
<td>Information not found</td>
<td>Information not available</td>
</tr>
<tr>
<td>Vicam (Vitamin B and C)</td>
<td>Look/Sound</td>
<td>Multivitamin combination</td>
<td>Information not available</td>
</tr>
<tr>
<td>Vinate 90</td>
<td>Look/Sound</td>
<td>Multivitamin combination</td>
<td>Information not available</td>
</tr>
<tr>
<td>Vinate-M</td>
<td>Look/Sound</td>
<td>Multivitamin combination</td>
<td>Information not available</td>
</tr>
<tr>
<td>Vioday (Discontinued)</td>
<td>Look/Sound</td>
<td>Nutritional vitamin supplement</td>
<td>Information not available</td>
</tr>
<tr>
<td>Virac (Discontinued)</td>
<td>Look/Sound</td>
<td>0.5%; 1.8%</td>
<td>Information not available</td>
</tr>
<tr>
<td>Viscoat (Chondroitin/Sodium Hyaluronate) (Discontinued)</td>
<td>Look/Sound</td>
<td>40 mg/30 mg per mL</td>
<td>Intracocular injection</td>
</tr>
<tr>
<td>Vita (Over-the-Counter)</td>
<td>Look/Sound</td>
<td>Multivitamin combination</td>
<td>Information not available</td>
</tr>
<tr>
<td>Vita-C (Over-the-Counter)</td>
<td>Look/Sound</td>
<td>1000 mg</td>
<td>Information not available</td>
</tr>
<tr>
<td>Viplapap (Acetaminophen) (Over-the-Counter)</td>
<td>Look/Sound</td>
<td>500 mg</td>
<td>500 mg every 4-6 hours</td>
</tr>
<tr>
<td>Vitaped (Discontinued)</td>
<td>Look/Sound</td>
<td>Multivitamin combination</td>
<td>Information not available</td>
</tr>
<tr>
<td>Vitara (Over-the-Counter)</td>
<td>Look/Sound</td>
<td>Female sexual aid/enhancer topical gel</td>
<td>Information not available</td>
</tr>
<tr>
<td>Vitrax (Hyaluronate Sodium) (Discontinued)</td>
<td>Look/Sound</td>
<td>3%</td>
<td>Information not available</td>
</tr>
</tbody>
</table>
### Appendix D: Potential confusing name with overlap in strength or dose

<table>
<thead>
<tr>
<th>Failure Mode: Name confusion</th>
<th>Causes (could be multiple)</th>
<th>Effects</th>
</tr>
</thead>
</table>
| **Vimpat** (Lacosamide)      | **Tablets:** 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg  
**Injection:** 10 mg/mL | **Usual dose:**  
Partial onset seizure: 200 mg/day to 400 mg/day (twice daily dosing); Maximum dose —— mg/day  
**Diabetic peripheral neuropathic pain:** —— |
| **Viracept** (Nelfinavir Mesylate) | Orthographic similarity (starts with 'Vi-' and ends in 't'; share -p-)  
Overlap in strength (250 mg) and frequency of administration (twice daily) | Orthographic differences in the names minimize the likelihood of medication error in the usual practice setting.  
**Rationale:**  
The risk for medication error is minimized by the orthographic differences in the names. Viracept is longer in length than Vimpat (8 letters vs. 6 letters). The downstroke in Viracept is not in the same location as Vimpat.  
Although they overlap in strength, the recommended dose for Viracept is 1,250 mg (five 250 mg tablets or two 625 mg tablets) twice daily or 750 mg (three 250 mg tablets) 3 times daily. The difference in dosing may help in distinguishing the name pair. |
| **Z-Pak** (Azithromycin)     | Orthographic similarity ('Z' and 'V' look similar; endings '-pak' and '-pat' look similar)  
Overlap in strength (250 mg) | Orthographic differences in the names minimize the likelihood of medication error in the usual practice setting.  
**Rationale:**  
The risk for medication error is minimized by the orthographic differences in the names. Z-pak is shorter in length than Vimpat (4 letters vs. 6 letters). Z-pak may be written with a hyphen after 'Z' which further distinguishes the name.  
Although they overlap in strength, Z-pak is generally prescribed without the strength since it is available in a single strength and is more likely prescribed as a unit (e.g. #1 UD). Z-pak is also only supplied for 5 days. |
<table>
<thead>
<tr>
<th>Drug</th>
<th>Orthographic similarity</th>
<th>Orthographic differences in the names minimize the likelihood of medication error in the usual practice setting.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zovirax (Acyclovir)</td>
<td>‘Z’ and ‘V’ look similar; ‘x’ and ‘t’ look similar</td>
<td><em>Rationale:</em> The risk for medication error is minimized by the orthographic differences in the names including the downstroke ‘p’ and upstroke ‘t’ in Vimpat and the lack of overlapping letters except for ‘i’ in the name pair. Additionally, the difference in frequency of administration (four or five times daily vs. twice daily) minimizes the risk.</td>
</tr>
<tr>
<td></td>
<td>Overlap in strength (200 mg)</td>
<td></td>
</tr>
<tr>
<td>Viread (Tenofovir Disoproxil Fumarate)</td>
<td>‘Vi’; upstroke at the end ‘d’ vs. ‘t’</td>
<td>Orthographic differences in the names minimize the likelihood of medication error in the usual practice setting.</td>
</tr>
<tr>
<td></td>
<td>Overlap in strength (300 mg)</td>
<td><em>Rationale:</em> The risk for medication error is minimized by the orthographic differences in the names including the downstroke ‘p’ in Vimpat and different middle letters. Also the difference in frequency of administration (once daily vs. twice daily) minimizes the risk.</td>
</tr>
<tr>
<td>Vamate (Hydroxyzine Pamoate)</td>
<td>‘V’; overlapping ‘m’ and ‘at’</td>
<td>Medication errors unlikely to occur in usual practice setting.</td>
</tr>
<tr>
<td></td>
<td>Overlap in strength (50 mg)</td>
<td><em>Rationale:</em> Limited information was available for Vamate. It was not found in common online drug references such as Drugs@FDA, Facts and Comparison or Micromedex. However, the active ingredient (hydroxyzine pamoate) is still available in the U.S. But since Vamate is not a well-known tradename for hydroxyzine, the likelihood of being prescribed as Vamate is low. Additionally, the orthographic differences minimize the risk of confusion. Vamate has no downstroke in the name and has an extra ‘e’ at the end.</td>
</tr>
</tbody>
</table>
2 Page(s) Withheld

/ Trade Secret / Confidential (b4)

Draft Labeling (b4)

Draft Labeling (b5)

Deliberative Process (b5)
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
-------------------
Judy Park
5/13/2008 01:05:27 PM
DRUG SAFETY OFFICE REVIEWER

Kellie Taylor
5/15/2008 10:50:39 AM
DRUG SAFETY OFFICE REVIEWER

Denise Toyer
5/15/2008 01:45:44 PM
DRUG SAFETY OFFICE REVIEWER